Abstract
In July 2007, all peritoneal dialysis (PD) patients in our hospital were switched from mupirocin to gentamicin ointment for daily application to the PD catheter exit site (CES). Our objective was to compare the efficacy of gentamicin and mupirocin in the prevention of catheter-related PD infections. We conducted an observational sequential cohort study to compare infectious outcomes with the 2 ointments. Mupirocin patients were followed retrospectively from January 2004 to June 2006 and gentamicin patients prospectively from July 2007 to December 2008. All patients were followed for 18 months following catheter insertion. Fifty-nine patients were included in the mupirocin arm and 37 patients in the gentamicin arm. Time to first infection (either CES or peritonitis) was similar between arms, with a probability of being infection-free at 12 months of 67% versus 53%, respectively (p=0.34). There were no differences in rates of overall infection (0.54 vs 0.56 infections per patient-year, respectively (p=0.94)) or peritonitis (0.41 vs 0.37 per patient-year, respectively (p=0.84). There were 5 pseudomonal infections in the mupirocin arm and none with gentamicin. It was concluded that topical gentamicin has comparable effectiveness to mupirocin for prevention of PD catheter-related infections.
Keywords: Gentamicin, mupirocin, peritoneal dialysis, peritonitis.
Current Drug Therapy
Title:Comparison of Gentamicin Ointment to Mupirocin Ointment for Prevention of Peritoneal Dialysis Catheter-Related Infections
Volume: 8 Issue: 1
Author(s): Katherine Wu, Erica Greanya, Karen Shalansky, Nadia Zalunardo, Guiyun Li and Suneet Singh
Affiliation:
Keywords: Gentamicin, mupirocin, peritoneal dialysis, peritonitis.
Abstract: In July 2007, all peritoneal dialysis (PD) patients in our hospital were switched from mupirocin to gentamicin ointment for daily application to the PD catheter exit site (CES). Our objective was to compare the efficacy of gentamicin and mupirocin in the prevention of catheter-related PD infections. We conducted an observational sequential cohort study to compare infectious outcomes with the 2 ointments. Mupirocin patients were followed retrospectively from January 2004 to June 2006 and gentamicin patients prospectively from July 2007 to December 2008. All patients were followed for 18 months following catheter insertion. Fifty-nine patients were included in the mupirocin arm and 37 patients in the gentamicin arm. Time to first infection (either CES or peritonitis) was similar between arms, with a probability of being infection-free at 12 months of 67% versus 53%, respectively (p=0.34). There were no differences in rates of overall infection (0.54 vs 0.56 infections per patient-year, respectively (p=0.94)) or peritonitis (0.41 vs 0.37 per patient-year, respectively (p=0.84). There were 5 pseudomonal infections in the mupirocin arm and none with gentamicin. It was concluded that topical gentamicin has comparable effectiveness to mupirocin for prevention of PD catheter-related infections.
Export Options
About this article
Cite this article as:
Wu Katherine, Greanya Erica, Shalansky Karen, Zalunardo Nadia, Li Guiyun and Singh Suneet, Comparison of Gentamicin Ointment to Mupirocin Ointment for Prevention of Peritoneal Dialysis Catheter-Related Infections, Current Drug Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574885511308010005
DOI https://dx.doi.org/10.2174/1574885511308010005 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fish Gelatin Hydrolysates as Antioxidant, Antihypertensive, and Antidiabetic: The Plausible Mechanisms
Mini-Reviews in Organic Chemistry Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?
Current Vascular Pharmacology Prothrombotic Potential of NSAID in Ischemic Heart Diesase
Mini-Reviews in Medicinal Chemistry Targeted-Therapy in Advanced Renal Cell Carcinoma
Current Medicinal Chemistry Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Is Hyperhomocyst(e)inemia A Humoral Predictor of Coronary Heart Disease?
Current Pharmaceutical Design Editorial:Circulating Biomarkers in Cardiovascular Diseases – A Field of Theoretical Research or Realistic Clinical Application?
Current Pharmaceutical Biotechnology Towards Newer Molecular Targets for Chronic Diabetic Complications
Current Vascular Pharmacology Preeclampsia: A Couples Disease with Maternal and Fetal Manifestations
Current Pharmaceutical Design Vitamin D and Vascular Disease
Current Vascular Pharmacology Higher Body Mass Index, Uric Acid Levels, and Lower Cholesterol Levels are Associated with Greater Weight Loss
Endocrine, Metabolic & Immune Disorders - Drug Targets Epinephrine and its Role in the Development of Obesity and Hypertension
Current Hypertension Reviews Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
Current Vascular Pharmacology Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Cholesterol Absorption Blockade with Ezetimibe
Current Drug Targets - Cardiovascular & Hematological Disorders The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Non-Alcoholic Fatty Liver Disease in HIV Infection Associated with Altered Hepatic Fatty Acid Composition
Current HIV Research